[1] World Health Organization. Consolidated guidelines on HIV prevention,diagnosis,treatment and care for key populations-2016Update[M]. Geneva:World Health Organization,2016.
|
[2] CLAUSEN LN. Factors associated with resolution and progression of HIV/hepatitis C virus infection[J]. Dan Med J,2014,61(4):B4838.
|
[3] CECEARELLI G,DETTORRE G,MANCONE M,et al. Accelerated coronary atherosclerosis after execution of percutaneous coronary intervention in patient with HIV/HCV coinfection:Case report and review of the literature[J]. Cardiovasc Revasc Med,2011,12(4):262-265.
|
[4] YOO TW,DONFIELD S,LAIL A,et al. Effect of hepatitis C virus(HCV)genotype on HCV and HIV-1 disease[J]. J Infect Dis,2005,191(1):4-10.
|
[5] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for hepatitis C(2019 version)[J]. J Clin Hepatol,2019,35(12):2670-2686.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2019年版)[J].临床肝胆病杂志,2019,35(12):2670-2686.
|
[6] Aids and Hepatitis C Professional Group,Society of Infectious Diseases,Chinese Medical Association,Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS(2018)[J]. Chin J Intern Med,2018,57(12):867-884.(in Chinese)中华医学会感染病分会艾滋病丙型肝炎学组,中国疾病预防控制中心.中国艾滋病诊疗指南(2018版)[J].中华内科杂志,2018,57(12):867-884.
|
[7] WANG M,YANG XL,ZHANG L,et al. Distribution characteristics of hepatitis C virus genotypes in Guizhou,China[J]. J Clin Hepatol,2020,36(2):309-313.(in Chinese)王梅,杨兴林,张流,等.贵州地区HCV感染者基因型分布特征[J].临床肝胆病杂志,2020,36(2):309-313.
|
[8] LI GY,SUN YM,LIU GW. Analysis on risk factors of HIV and HCV infections among drug users in Beijing in 2018[J]. Int J Virol,2019,26(6):387-391.(in Chinese)李桂英,孙燕鸣,刘国武.北京市吸毒人群感染HIV和丙型肝炎病毒危险因素分析[J].国际病毒学杂志,2019,26(6):387-391.
|
[9] HERNANDEZ MD,SHERMAN KE. HIV/hepatitis C coinfection natural history and disease progression[J]. Curr Opin HIV AIDS,2011,6(6):478-482.
|
[10] PLATT L,EASTERBROOK P,GOWER E,et al. Prevalence and burden of HCV co-infection in people living with HIV:A global systematic review and meta-analysis[J]. Lancet Infect Dis,2016,16(7):797-808.
|
[11] ZHANG F,ZHU H,WU Y,et al. HIV,hepatitis B virus,and hepatitis C virus coinfection in patients in the China National Free Antiretroviral Treatment Program,2010-12:aretrospective observational cohort study[J]. Lancet Infect Dis,2014,14(11):1065-1072.
|
[12] JIN ZY,LIU X,DING YY,et al. Cancer risk factors among people living with HIV/AIDS in China:A systematic review and meta-analysis[J]. Sci Rep,2017,7(1):4890.
|
[13] MARTINELLO M,AMIN J,MATTHEWS GV,et al. Prevalence and disease burden of hcv coinfection in hiv cohorts in the Asia Pacific Region:A systematic review and meta-analysis[J].AIDS Rev,2016,18(2):68-80.
|
[14] XIE NH,WANG X,WU S,et al. Epidemiological characteristics and influencing factors of HBV and HCV coinfections among patients with HIV/AIDS in Wuhan city[J]. Acta Med Univ Sci Technol Huazhong,2019,18(2):183-188.(in Chinese)谢年华,王夏,吴斯,等.武汉市HIV/AIDS合并HBV/HCV感染的流行特征和影响因素分析[J].华中科技大学学报(医学版),2019,18(2):183-188.
|
[15] CHEN HX,WANG H,LEI YH,et al. Advances in genotyping and molecular epidemiology of hepatitis C virus[J]. Int J Virol,2019,26(5):348-351.(in Chinese)陈红霞,王海,类延花,等.丙型肝炎病毒基因分型及其分子流行病学研究进展[J].国际病毒学杂志,2019,26(5):348-351.
|
[16] MESSINA JP,HUMPHREYS I,FLAXMAN A,et al. Global distribution and prevalence of hepatitis C virus genotypes[J].Hepatology,2015,61(1):77-87.
|
[17] SALEMOVIC D,PESIC-PAVLOVIC I,JEVTOVIC D,et al. Intravenous drug use-an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients[J]. Arch Med Sci,2017,13(3):652-658.
|
[18] CHEN W,LIAO B,HU F,et al. Changing epidemiology of hepatitis C virus genotype among patients with human immunodeficiency virus/hepatitis C virus coinfection in China[J].PLo S One,2016,11(9):e0161844.
|
[19] WANG YK,CHEN XC,WANG JB,et al. Molecular transmission clusters on HCV genotypes among newly reported HIV/HCV co-infection in Dehong Dai and Jingpo autonomous prefecture of Yunnan province,2016[J]. Chin J Epidemiol,2019,40(2):191-195.(in Chinese)王译葵,陈晓晨,王继宝,等.德宏傣族景颇族自治州2016年HIV/HCV合并感染者HCV分子传播簇分析[J].中华流行病学杂志,2019,40(2):191-195.
|
[20] DENG HH,LI XQ,GAO HB,et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV monoinfection in GuangZhou[J]. J Prac Hepatol,2019,22(5):656-659.(in Chinese)邓浩辉,李晓强,高洪波,等.HIV/HCV混合感染者与HCV感染者感染HCV基因型分析[J].实用肝脏病杂志,2019,22(5):656-659.
|
[21] JI YJ,ZHAO M,SUN YL,et al. Observe the pathological changes of liver tissues in patients infected with hepatitis C virus and human immunodeficiency virus[J]. Chin J Intern Med,2006,45(11):939-941.(in Chinese)吉英杰,赵敏,孙艳玲,等.丙型肝炎病毒和人类免疫缺陷病毒合并感染者肝组织病理学观察[J].中华内科杂志,2006,45(11):939-941.
|
[22] ZHANG X,XU J,PENG H,et al. HCV coinfection associated with slower disease progression in HIV-infected former plasma donors nave to ART[J]. PLo S One,2008,3(12):e3992.
|
[23] LIU JH,ZHAO Y,SUN HQ,et al. Effect of HCV on disease progression in patients with HIV/HCV coinfection[J]. J Clin Hepatol,2014,30(6):501-504.(in Chinese)刘金花,赵艳,孙焕芹,等.HCV对HIV/HCV共感染患者病情进展的影响[J].临床肝胆病杂志,2014,30(6):501-504.
|
[24] HERNANDEZ MD,SHERMAN KE. HIV/hepatitis C coinfection natural history and disease progression[J]. Curr Opin HIV AIDS,2011,6(6):478-482.
|
[25] KIRK GD,MEHTA SH,ASTEMBORSKI J,et al. HIV,age,and the severity of hepatitis C virus-related liver disease:A cohort study[J]. Ann Intern Med,2013,158(9):658-666.
|
[26] AMOLD DM,JULIAN JA,WALKER IR,et al. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up[J]. Blood,2006,108(2):460-464.
|
[27] MASTROIANNI CM,LICHTNER M,MASCIA C,et al. Molecular mechanisms of liver fibrosis in HIV/HCV coinfection[J]. Int J Mol Sci,2014,15(6):9184-9208.
|
[28] ERQOU S,MOHANTY A,MURTAZA KASI P,et al. Predictors of mortality among United States veterans with human immunodeficiency virus and hepatitis C virus coinfection[J]. ISRN Gastroenterol,2014,2014:764540.
|
[29] RABOUD J,ANEMA A,SU D,et al. Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy[J]. HIV Clin Trials,2012,13(2):90-102.
|
[30] REICHE EM,BONAMETTI AM,MORIMOTO HK,et al. Epidemiological,immunological and virological characteristics,and disease progression of HIV-1/HCV co-infected patients from a southern Brazilian population[J]. Int J Mol Med,2008,21(3):387-395.
|
[31] SENGUPTA S,POWELL E,KONG L,et al. Effects of HCV on basal and tat-induced HIV LTR activation[J]. PLo S One,2013,8(6):e64956.
|
[32] LI CX,LIU J,GUAN W,et al. Analysis of the influential factors on treatment effect of direct-acting antiviral agents in patients with HIV/HCV co-infection[J]. J Kunming Med Univ,2019,40(8):102-106.(in Chinese)李重熙,刘俊,关玮,等.DAAs对HIV合并丙型肝炎治疗效果的影响因素[J].昆明医科大学学报,2019,40(8):102-106.
|